Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Cytosorbents (CTSO) EBT (2016 - 2025)

Cytosorbents' EBT history spans 15 years, with the latest figure at -$6.5 million for Q4 2025.

  • Quarterly results put EBT at -$6.5 million for Q4 2025, down 363.94% from a year ago — trailing twelve months through Dec 2025 was -$15.8 million (down 49.85% YoY), and the annual figure for FY2025 was -$9.6 million, up 10.1%.
  • EBT for Q4 2025 was -$6.5 million at Cytosorbents, down from -$3.6 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $14.5 million in Q4 2023 to a low of -$12.2 million in Q3 2022.
  • The 5-year median for EBT is -$5.4 million (2021), against an average of -$4.7 million.
  • The sharpest move saw EBT crashed 662.9% in 2021, then skyrocketed 881.47% in 2023.
  • Year by year, EBT stood at -$10.0 million in 2021, then soared by 81.49% to -$1.9 million in 2022, then skyrocketed by 881.47% to $14.5 million in 2023, then plummeted by 83.03% to $2.5 million in 2024, then tumbled by 363.94% to -$6.5 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at -$6.5 million, -$3.6 million, and -$4.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.